SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: sam who wrote (5180)8/19/1998 1:49:00 PM
From: Steve Fancy  Read Replies (2) | Respond to of 6136
 
She's selling up a storm today. Again, can't help buy wonder if this is short covering or something else is up. Sam, where have you been hearing buyout talk? I've only seen it mentioned in casual conversation here and Yahoo. Options activity, although some reasonable volume at a couple strikes today, doesn't seem to suggest anything unusual.

I think it's shorts...not much reason before today to cover. Doesn't seem that a long upgrade from neutral to buy should have this impact though.

sf



To: sam who wrote (5180)8/19/1998 1:55:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 6136
 
Little credence or not, what rumors are you hearing? :-)

I haven't heard a single rumor, but rationale commands that offers are on the table at a hefty premium.



To: sam who wrote (5180)8/25/1998 9:06:00 AM
From: sam  Read Replies (3) | Respond to of 6136
 
Remune news:
Message 5580643

Also, Bloomberg reports that Prudential analyst Caroline Copithorne has some things to say about Remune (in her comments on IMNR). She thinks Remune may have a large market in developing countries where the high cost and complex dosing of antiviral therapy can be prohibitive.